Zydus Cadila’s US Firm Gets US Approval To Market Roflumilast Tablets

Cadila Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets. In the strength of 500 mcg indicated to reduce…
Read More...